BODI Earnings

BODI reported its earnings on 2026-05-12, showcasing a revenue of against an estimate of 52.24M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.02 by 0%. The stock experienced a -2.63% price change on the earnings day and a -21.47% change over the next five days, reflecting market reactions to the results.

Following BODI's earnings announcement on 2026-05-12, the stock price moved by -2.63% on the day of the release. Over the subsequent five days, it saw a -21.47% change. Historically, BODI's stock price tends to shift by an average of -2.7% in the 10 days leading up to earnings and 4.54% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate BODI's annual revenue to reach 57.59M, while the EPS is projected at -0.23. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between BODI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BODI's stock price typically moves by -2.7% in the 10 days before its earnings and 4.54% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.23 and revenue of 57.59M.

The earnings call revealed a decline in revenue, adjusted EBITDA, net cash, and free cash flow, indicating financial struggles. The 10% revenue drop and 58% EBITDA decrease signal weak financial performance, likely leading to a negative stock reaction. No positive catalysts or strategic initiatives were discussed to offset these declines. Without a market cap, we assume a moderate reaction, categorizing the stock price movement as 'Negative' within the -2% to -8% range.